Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

Bone Marrow Transplantation

Volumn 30, Issue 12, 2002, Pages 797-804

  Hale, G ^a   Slavin, S ^b   Goldman, J M ^c   Mackinnon, S ^d   Giralt, S ^e   Waldmann, H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Allografting; Autografting; B CLL; Campath; CD52; Nonmyeloablative regimens

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; PENTOSTATIN; PURINE DERIVATIVE; RITUXIMAB; THYMOCYTE ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; DONOR; DRUG EFFICACY; DRUG MECHANISM; EPSTEIN BARR VIRUS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL; PROGNOSIS; RADIATION; RECIPIENT; REVIEW; STEM CELL; STEM CELL MOBILIZATION; T LYMPHOCYTE; VIRUS CARCINOGENESIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE DEPLETION; LYMPHOMA; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE;

EID: 0036952617     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703733     Document Type: Review

References (74)

1. Weiden PL, Sullivan KM, Fluornoy N et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med 1981; 304: 1529-1533.
2. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
3. Waldmann H, Polliak A, Hale G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2: 483-486.
4. Slavin S, Waldmann H, Or R et al. Prevention of graft-vs-host disease in allogeneic transplantation for leukemia by T cell depletion in vitro prior to transplantation. Transplant Proc 1985; 17: 465-467.
5. Cobbold SP, Martin G, Qin S, Waldmann H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 1986; 323: 164-166.
6. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994; 13: 597-611.
7. Slavin S, Strober S, Fuks Z, Kaplan HS. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. Science 1976; 193: 1252-1254.
8. Slavin S, Naparstek E, Aker M et al. The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders. Transplant Proc 1989; 21: 3053-3054.
9. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther 1991; 49: 239-268.
10. Williamson L, Wimperis J, Wood M, Woodcock B. Fludarabine treatment and transfusion-associated graft-versus-host disease. Lancet 1996; 348: 4723.
11. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137-144.
12. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807-812.
13. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
14. Keating MJ, Flinn I, Vinay J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
15. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukaemia treated with CAMPATH-1H. Blood 2001; 98: 1721-1726.
16. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
17. Kennedy B, Rawstron A, Carter C et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245-2247.
18. Faderl S, Thomas DA, O'Brien S et al. An exploratory study of the combination of monoclonal antibodies CAMPATH-1H and Rituximab in the treatment of CD52 and CD20-positive chronic lymphocytic disorders. Blood 2001; 98: 365A.
19. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas. A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lympoma. J Clin Oncol 1998; 16: 3257-3263.
20. Neudorf SM, Rybka W, Ball E et al. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow. J Hematother 1997; 6: 351-359.
21. Cornelissen JJ, Fibbe WE, Schattenberg AV et al. A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21 (Suppl. 3): S66-S70.
22. Weiss L, Margel S, Slavin S. Depletion of human lymphocytes from peripheral blood and bone marrow by affinity ligands conjugated to agarose-polyacrolein microsphere beads. Appl Biochem Biotechnol 1986; 13: 87-96.
23. Frame JN, Collins NH, Cartagena T et al. T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads. Transplantation 1989; 47: 984-988.
24. Jeong DC, Han CW, Jin JY et al. Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility. Exp Hematol 1999; 27: 1219-1225.
25. Schattenberg A, Preijers F, Mensink E et al. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase. Bone Marrow Transplant 1997; 19: 1205-1212.
26. Schaap N, Schattenberg A, Bar B et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. Br J Haematol 1997; 98: 750-759.
27. + stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. Bone Marrow Transplant 1998; 22: 947-955.
28. Noga SJ, Seber A, Davis JM et al. CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment. J Hematother 1998; 7: 151-157.
29. + cell immunoaffinity selection and in vitro Campath-1M treatment: clinical implications for bone marrow transplantation and donor leukocyte therapy. Bone Marrow Transplant 1997; 20: 599-605.
30. Dao MA, Nolta JA. CD34: To select or not to select? That is the question. Leukemia 2000; 14: 773-776.
31. + cells. Exp Hematol 1998; 26: 353-360.
32. - cells in vivo. Ann NY Acad Sci 1999; 872: 220-222.
33. Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581-4590.
34. Jacobs P, Wood L, Fullard L et al. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994; 13: 763-769.
35. Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69-76.
36. Rebello P, Cwynarski K, Varughese M et al. Phamacokinetics of Campath-1H in bone marrow transplant patients. Cytotherapy 2001; 3: 261-267.
37. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
38. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-2216.
39. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH users. Blood 1998; 91: 3079-3083.
40. Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15: 387-393.
41. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of CAMPATH-1H in delaying immune reconstitution but limiting transplant-related mortality. Blood 2002; 99: 4357-4363.
42. D'Sa SP, Peggs KS, Thuraisundaram D et al. CAMPATH-1H-containing nonmyeloablative allogeneic stem cell transplantation for myeloma results in delayed T cell reconstitution and a high incidence of viral infections, but low infection-related mortality. Blood 2001; 98: 203a (Abstr. 847).
43. Potter M, Grace S, Ethell M et al. High rate of CMV reactivation (but not disease) in recipient of allogeneic transplants conditioned with CAMPATH-1H. Bone Marrow Transplant 2000; 25 (Suppl. 1): 135.
44. Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001; 72: 1460-1463.
45. Davison GM, Novitzky N, Kline A et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000; 69: 1341-1347.
46. Akashi K, Kondo M, Weissman, IL. Role of interleukin-7 in T-cell development from hematopoietic stem cells. Immunol Rev 1998; 165: 13-28.
47. Fry TJ, Christensen BL, Komschlies KL et al. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood 2001; 97: 1525-1533.
48. Grigg A, Bardy P, Byron K et al. Fludarabine-based nonmyeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant 1999; 23: 107-110.
49. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
50. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
51. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
52. Champlin R, Khouri I, Kornblau S et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am 1999; 13: 1041-1058.
53. Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans (editorial). Bone Marrow Transplant 2000; 25: 345-350.
54. Nagler A, Slavin S., Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028.
55. Cull GM, Haynes AP, Byrne JL et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol 2000; 108: 754-760.
56. Flinn IW, Vogelsang G. Bone marrow transplantation for chronic lymphocytic leukemia. Semin Oncol 1998; 25: 60-64.
57. Dreger P, von Neuhoff N, Kuse R et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer 1998; 77: 2291-2297.
58. + cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: complete remission of lymphoma with control of autoimmune complications. Bone Marrow Transplant 1999; 24: 215-217.
59. Itala M, Pelliniemi TT, Rajamaki A, Remes K. Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant 1997; 19: 647-651.
60. Scime R, Indovina A, Santoro A et al. PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. Bone Marrow Transplant 1998; 22: 1159-1165.
61. Schey S, Ahsan G, Jones R. Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study. Bone Marrow Transplant 1999; 24: 989-993.
62. Dyer MJ, Kelsey SM, Mackay HJ et al. In vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol 1997; 97: 669-672.
63. Kennedy S, Rawstron A, Evans P et al. Campath-1H therapy in 29 patients with refractory CLL: 'true' complete remission is an attainable goal. Blood 1999; 94 (Suppl. 1): 603a (Abstr. 2683).
64. Michallet M, Archimbaud E, Bandini G et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 1996; 124: 311-315.
65. Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748-758.
66. Pavletic, ZS, Arrowsmith, ER, Bierman PJ et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 717-722.
67. Provan D, Bartlett-Pandite L, Zwicky C et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228-2235.
68. Lush RJ, Haynes AP, Byrne JL et al. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPAH (+/-fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy 2001; 3: 203-210.
69. Carrum G, Przepiorka D, Popat U et al. Submyeloablative conditioning regimens using anti-lymphocyte antibodies for allogeneic stem cell transplantation. Blood 2001; 98: 184a (Abstr. 775).
70. Rizzieri DA, Long GD, Vredenburgh JJ et al. Nonmyeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells. Blood 2001; 98: 420a (Abstr. 1764).
71. Rizzieri DA, Long GD, Vredenburgh JJ et al. Nonmyeloablative transplantation using CAMPATH 1H for T depletion of mismatched, related donor peripheral blood stem cells. Blood 2001; 98, 669a (Abstr. 2805).
72. Rabinowe SN, Soiffer RJ, Gribben JG et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366-1376.
73. Bandini G, Michallet M, Rosti G, Tura S. Bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1991; 7: 251-253.
74. Toze CL, Shepherd JD, Connors JM et al. Allografting for indolent lymphoid neoplasms. Ann Oncol 1994; 12: 748-758.